Pfizer Aktie
WKN: 852009 / ISIN: US7170811035
|
30.04.2026 20:35:04
|
Pfizer Just Scored a Win That Wall Street Can't Ignore
Pfizer (NYSE: PFE) recently reached settlements with three generic drugmakers -- Hikma, Cipla, and Dexcel -- to extend the patent protection of Vyndamax, one of its best-selling drugs, through June 2031. Let's see why that deal is bullish for Pfizer's stock.Image source: Getty Images.Vyndamax, which treats heart problems in adults with cardiomyopathy, along with its related drugs, generated $6.3 billion in revenue for Pfizer in 2025. That represented 17% growth from 2024 and accounted for 10% of its top line. Vyndamax's rising sales offset its slowing sales of COVID vaccines and drugs, but its key patents will start expiring in 2028 and 2029.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Pfizer Inc.
Analysen zu Pfizer Inc.
| 01.06.26 | Pfizer Buy | Jefferies & Company Inc. | |
| 01.06.26 | Pfizer Neutral | JP Morgan Chase & Co. | |
| 28.05.26 | Pfizer Underweight | Barclays Capital | |
| 06.05.26 | Pfizer Kaufen | DZ BANK | |
| 06.05.26 | Pfizer Neutral | UBS AG |
Aktien in diesem Artikel
| Pfizer Inc Cert.Deposito Arg.Repr. 0.5 Shs | 9 525,00 | -2,41% |
|
| Pfizer Inc. | 22,07 | 0,09% |
|